TY - JOUR
T1 - The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in korea
T2 - Results of a korean expert consensus
AU - Park, Eun Jung
AU - Kim, Hyungjin
AU - Jung, Seung Min
AU - Sung, Yoon Kyoung
AU - Baek, Han Joo
AU - Lee, Jisoo
N1 - Funding Information:
The Task Force gratefully acknowledges the contribution of the consensus group members for participating in the agreement process of the statements and for generously sharing their expert opinions. We would also like to acknowledge KCR Executive Committee for the endorsement of the Expert Consensus.
Publisher Copyright:
© Korean Association of Internal Medicine. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bD-MARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
AB - Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bD-MARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
KW - Ankylosing
KW - Arthritis
KW - Biological disease-modifying antirheumatic drugs
KW - Expert consensus
KW - Inflammatory arthritis
KW - Rheumatoid
KW - Spondylitis
UR - http://www.scopus.com/inward/record.url?scp=85077863401&partnerID=8YFLogxK
U2 - 10.3904/kjim.2019.411
DO - 10.3904/kjim.2019.411
M3 - Article
C2 - 31935319
AN - SCOPUS:85077863401
VL - 35
SP - 41
EP - 59
JO - Korean Journal of Internal Medicine
JF - Korean Journal of Internal Medicine
SN - 1226-3303
IS - 1
ER -